Host-directed therapies for antimicrobial resistant respiratory tract infections
PURPOSE OF REVIEWAntimicrobial-resistant respiratory tract infections (AMR-RTIs) are increasing, presenting important management challenges worldwide. Current management of AMR-RTI patients focuses on pathogen-directed antimicrobial treatment. Overt lung inflammation, parenchymal damage, and ineffective immune activation perpetrate increased patient morbidity and mortality. Immunomodulatory and tissue-regenerative host-directed therapies (HDT) may improve treatment outcomes. HDTs under investigation for improving AMR-RTI treatment outcomes are reviewed. RECENT FINDINGSVarious HDTs are being developed or evaluated for adjunctive AMR-RTI treatment. α-1 antitrypsin was shown to reduce Pseudomonas aeruginosa burden in the airways of cystic fibrosis patients. Cellular therapy by reinfusing autologous bone marrow-derived MSCs into MDR/XDR-TB patients shows promise, whereas adjunctive T cell-based therapies are considered. Cytotoxic therapy using etoposide, a topoisomerase II-inhibiting anticancer drug extends survival of patients with severe influenza H1N1 infection-induced hemophagocytic lymphohistiocytosis. Two other novel HDT candidates, DAS181 and resveratrol show antiinfluenza effects. Novel kinase inhibitors SB203580 (MAPK-2 antagonist) and LY294002 (phosphoinositide-3 kinases antagonist) exhibit promising anti-MERS-CoV activity. Palivizumab, an anti-RSV monoclonal antibody, effectively prevents RSV infection in high-risk paediatric populations. T-cell therapy is currently considered for adjunctive HDT of azole-resistant pulmonary aspergillosis. SUMMARYNovel HDTs may revolutionize future treatment regimens for AMR-RTIs. Well designed multisite clinical trials are now necessary to accelerate progress..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Current opinion in pulmonary medicine - 22(2016), 3, Seite 203-211 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maeurer, Markus [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1097/MCP.0000000000000271 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1973303299 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1973303299 | ||
| 003 | DE-627 | ||
| 005 | 20211208215826.0 | ||
| 007 | tu | ||
| 008 | 160427s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MCP.0000000000000271 |2 doi | |
| 028 | 5 | 2 | |a PQ20160610 |
| 035 | |a (DE-627)OLC1973303299 | ||
| 035 | |a (DE-599)GBVOLC1973303299 | ||
| 035 | |a (PRQ)p961-621d15b26c144a5253e66413ce63282cf50b6d8b62d892b3b191c549b329a4e10 | ||
| 035 | |a (KEY)0238486820160000022000300203hostdirectedtherapiesforantimicrobialresistantresp | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ZDB |
| 100 | 1 | |a Maeurer, Markus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Host-directed therapies for antimicrobial resistant respiratory tract infections |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a PURPOSE OF REVIEWAntimicrobial-resistant respiratory tract infections (AMR-RTIs) are increasing, presenting important management challenges worldwide. Current management of AMR-RTI patients focuses on pathogen-directed antimicrobial treatment. Overt lung inflammation, parenchymal damage, and ineffective immune activation perpetrate increased patient morbidity and mortality. Immunomodulatory and tissue-regenerative host-directed therapies (HDT) may improve treatment outcomes. HDTs under investigation for improving AMR-RTI treatment outcomes are reviewed. RECENT FINDINGSVarious HDTs are being developed or evaluated for adjunctive AMR-RTI treatment. α-1 antitrypsin was shown to reduce Pseudomonas aeruginosa burden in the airways of cystic fibrosis patients. Cellular therapy by reinfusing autologous bone marrow-derived MSCs into MDR/XDR-TB patients shows promise, whereas adjunctive T cell-based therapies are considered. Cytotoxic therapy using etoposide, a topoisomerase II-inhibiting anticancer drug extends survival of patients with severe influenza H1N1 infection-induced hemophagocytic lymphohistiocytosis. Two other novel HDT candidates, DAS181 and resveratrol show antiinfluenza effects. Novel kinase inhibitors SB203580 (MAPK-2 antagonist) and LY294002 (phosphoinositide-3 kinases antagonist) exhibit promising anti-MERS-CoV activity. Palivizumab, an anti-RSV monoclonal antibody, effectively prevents RSV infection in high-risk paediatric populations. T-cell therapy is currently considered for adjunctive HDT of azole-resistant pulmonary aspergillosis. SUMMARYNovel HDTs may revolutionize future treatment regimens for AMR-RTIs. Well designed multisite clinical trials are now necessary to accelerate progress. | ||
| 540 | |a Nutzungsrecht: Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 700 | 1 | |a Rao, Martin |4 oth | |
| 700 | 1 | |a Zumla, Alimuddin |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Current opinion in pulmonary medicine |d Hagerstown, Md. [u.a.] : Wolters Kluwer Lippincott Williams & Wilkins, 1995 |g 22(2016), 3, Seite 203-211 |w (DE-627)188868607 |w (DE-600)1285505-4 |w (DE-576)053640039 |x 1070-5287 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2016 |g number:3 |g pages:203-211 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1097/MCP.0000000000000271 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26989822 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2016 |e 3 |h 203-211 | ||